Abstract
Protein-losing enteropathy (PLE) is a rare complication of Fontan palliation associated with significant morbidity and mortality. It is characterized by the loss of serum proteins into the intestinal lumen, and its pathophysiology likely involves enteral inflammation. Budesonide, an oral steroid, is an attractive treatment option because of its potent enteral activity and minimal systemic side effects. A single-center, retrospective review of Fontan-palliated PLE patients treated with oral budesonide for 6 months or longer was performed. The patient characteristics reviewed were demographics, anatomic diagnosis, budesonide treatment (dose and duration), other medications and therapeutic interventions, hospitalizations, serum albumin levels, medical complications, and patient status at the time of follow-up assessment. The study enrolled 10 patients representing 228 patient-months of on-therapy follow-up evaluation. Serum albumin levels increased after initiation of budesonide for 90% of the patients, and clinical evidence of fluid overload improved for 60% of them. Symptomatic improvement was reported in 80% of the cases. During the treatment period, 50% of the patients met the primary end point of death or cardiac transplantation. In this series of PLE patients, oral budesonide therapy was associated with significant symptomatic improvement and sustained increases in serum albumin. However, budesonide therapy may not alter the long-term outcome for patients with advanced PLE.
Similar content being viewed by others
References
Bhagirath KM, Tam JW (2007) Resolution of protein-losing enteropathy with low-molecular-weight heparin in an adult patient with Fontan palliation. Ann Thorac Surg 84:2110–2112
Bode L, Eklund EA, Murch S, Freeze HH (2005) Heparan sulfate depletion amplifies TNF-alpha-induced protein leakage in an in vitro model of protein-losing enteropathy. Am J Physiol Gastrointest Liver Physiol 288:G1015–G1023
Bode L, Murch S, Freeze HH (2006) Heparan sulfate plays a central role in a dynamic in vitro model of protein-losing enteropathy. J Biol Chem 281:7809–7815
Cheung YF, Tsang HY, Kwok JS (2002) Immunologic profile of patients with protein-losing enteropathy complicating congenital heart disease. Pediatr Cardiol 23:587–593
Donnelly JP, Rosenthal A, Castle VP, Holmes RD (1997) Reversal of protein-losing enteropathy with heparin therapy in three patients with univentricular hearts and Fontan palliation. J Pediatr 130:474–478
Edsbacker S, Andersson T (2004) Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn’s disease. Clin Pharmacokinet 43:803–821
Feldt RH, Driscoll DJ, Offord KP, Cha RH, Perrault J, Schaff HV, Puga FJ, Danielson GK (1996) Protein-losing enteropathy after the Fontan operation. J Thorac Cardiovasc Surg 112:672–680
Grattan MJ, McCrindle BW (2010) Recurrent exacerbations of protein-losing enteropathy after initiation of growth hormone therapy in a Fontan patient controlled with spironolactone. Congenit Heart Dis 5:165–167
Hoashi T, Ichikawa H, Ueno T, Kogaki S, Sawa Y (2009) Steroid pulse therapy for protein-losing enteropathy after the Fontan operation. Congenit Heart Dis 4:284–287
Kim SJ, Park IS, Song JY, Lee JY, Shim WS (2004) Reversal of protein-losing enteropathy with calcium replacement in a patient after Fontan operation. Ann Thorac Surg 77:1456–1457
Koch A, Hofbeck M, Feistel H, Buheitel G, Singer H (1999) Circumscribed intestinal protein loss with deficiency in CD4 + lymphocytes after the Fontan procedure. Eur J Pediatr 158:847–850
Lemes V, Murphy AM, Osterman FA, Laschinger JC, Kan JS (1998) Fenestration of extracardiac Fontan and reversal of protein-losing enteropathy: case report. Pediatr Cardiol 19:355–357
Meadows J, Gauvreau K, Jenkins K (2008) Lymphatic obstruction and protein-losing enteropathy in patients with congenital heart disease. Congenit Heart Dis 3:269–276
Mertens L, Hagler DJ, Sauer U, Somerville J, Gewillig M (1998) Protein-losing enteropathy after the Fontan operation: an international multicenter study. PLE study group. J Thorac Cardiovasc Surg 115:1063–1073
Ninan M, Myers JL (1998) Conversion of the atriopulmonary Fontan connection to a total cavopulmonary connection. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 1:23–30
Ostrow AM, Freeze H, Rychik J (2006) Protein-losing enteropathy after Fontan operation: investigations into possible pathophysiologic mechanisms. Ann Thorac Surg 82:695–700
Petko M, Myung RJ, Wernovsky G, Cohen MI, Rychik J, Nicolson SC, Gaynor JW, Spray TL (2003) Surgical reinterventions following the Fontan procedure. Eur J Cardiothorac Surg 24:255–259
Rao PS (2007) Protein-losing enteropathy following the Fontan operation. J Invasive Cardiol 19:447–448
Reinhardt Z, Uzun O, Bhole V, Ofoe V, Wilson D, Onuzo O, Wright JG, Stumper O (2010) Sildenafil in the management of the failing Fontan circulation. Cardiol Young 20:522–525
Rychik J (2007) Protein-losing enteropathy after Fontan operation. Congenit Heart Dis 2:288–300
Rychik J, Gui-Yang S (2002) Relation of mesenteric vascular resistance after Fontan operation and protein-losing enteropathy. Am J Cardiol 90:672–674
Rychik J, Piccoli DA, Barber G (1991) Usefulness of corticosteroid therapy for protein-losing enteropathy after the Fontan procedure. Am J Cardiol 68:819–821
Ryerson L, Goldberg C, Rosenthal A, Armstrong A (2008) Usefulness of heparin therapy in protein-losing enteropathy associated with single-ventricle palliation. Am J Cardiol 101:248–251
Thacker D, Patel A, Dodds K, Goldberg DJ, Semeao E, Rychik J (2010) Use of oral budesonide in the management of protein-losing enteropathy after the Fontan operation. Ann Thorac Surg 89:837–842
Uzun O, Wong JK, Bhole V, Stumper O (2006) Resolution of protein-losing enteropathy and normalization of mesenteric Doppler flow with sildenafil after Fontan. Ann Thorac Surg 82:e39–e40
Vyas H, Driscoll DJ, Cetta F, Loftus CG, Connolly HM (2006) Gastrointestinal bleeding and protein-losing enteropathy after the Fontan operation. Am J Cardiol 98:666–667
Vyas H, Driscoll DJ, Cabalka AK, Cetta F, Hagler DJ (2007) Results of transcatheter Fontan fenestration to treat protein losing enteropathy. Catheter Cardiovasc Interv 69:584–589
Ringel RE, Peddy SB (2003) Effect of high-dose spironolactone on protein-losing enteropathy in patients with Fontan palliation of complex congenital heart disease. Am J Cardiol 91:1031–1032 A1039
Zellers TM, Brown K (1996) Protein-losing enteropathy after the modified Fontan operation: oral prednisone treatment with biopsy and laboratory proved improvement. Pediatr Cardiol 17:115–117
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schumacher, K.R., Cools, M., Goldstein, B.H. et al. Oral Budesonide Treatment for Protein-Losing Enteropathy in Fontan-Palliated Patients. Pediatr Cardiol 32, 966–971 (2011). https://doi.org/10.1007/s00246-011-0029-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00246-011-0029-2